News
The FDA has granted accelerated approval to semaglutide (Wegovy; Novo Nordisk) injection 2.4 mg for the treatment of adults with metabolic dysfunction–associated steatohepatitis (MASH) with moderate ...
Wegovy is now approved by FDA for the treatment of adults with noncirrhotic MASH with moderate to advanced liver fibrosis.
The FDA has granted accelerated approval of Wegovy® (semaglutide) for adults with moderate to advanced metabolic ...
MedPage Today on MSN6d
Semaglutide Gets FDA Greenlight for MASH
The glucagon-like peptide-1 (GLP-1) receptor agonist gained accelerated approval for patients with MASH and moderate to ...
Wegovy is now approved by the FDA to treat metabolic-associated steatohepatitis in adults with moderate-to-advanced fibrosis ...
The FDA has approved Wegovy for the treatment of adults with noncirrhotic metabolic dysfunction-associated steatohepatitis ...
Wegovy is the first GLP-1 drug approved to treat adults with metabolic dysfunction-associated steatohepatitis (MASH). An ...
With a new endorsement from the FDA, Novo Nordisk’s Wegovy has picked up its third indication and become the second drug ...
Pharmaceutical Technology on MSN7d
Wegovy becomes first GLP-1RA to gain FDA MASH approval
Novo Nordisk's Wegovy has received accelerated approval for use in patients with metabolic dysfunction-associated ...
Everyday Health on MSN5d
People With Weight-Related Chronic Liver Disease Have a New Treatment Option
The U.S. Food and Drug Administration approved the obesity drug Wegovy for people with the chronic liver disease known as ...
The FDA has approved semaglutide for treating MASH, a significant advancement in liver disease management. Semaglutide, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback